Afatinib

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 27.02.2022

Dieser Artikel auf Deutsch

Synonym(s)

Afatinibdimaleate; Afatinibi dimaleas; Afatinibum; BIBW 2992

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Afatinib (molecular formula: C24H25ClFN5O3), an oral 4-aniline quinazoline derivative (the compound is present in drugs as afatinib dimaleate), is an antitumor agent in the tyrosine kinase inhibitor group used for the treatment of advanced or metastatic non-small cell lung cancer with activating EGFR mutations (Sequist E V et al 2013; Yang J CH et al 2013).

Spectrum of actionThis section has been translated automatically.

The effects are based on covalent binding to the kinase domains of EGFR (Epidermal Growth Factor Receptor), HER2 and HER4. Afatinib thus causes an inhibition of the ErbB signalling pathway. Afatinib is taken once daily on an empty stomach in a dosage of 40mg/day p.o. The drug has a long half-life of up to 37 hours.

IndicationThis section has been translated automatically.

EGFR tyrosine kinase inhibitor (TKI)-naive adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations

Locally advanced or metastatic NSCLC with squamous epithelial histology progressing under or after platinum-based chemotherapy

Undesirable effectsThis section has been translated automatically.

The most common possible adverse effects include diarrhea, exanthema, epistaxis, stomatitis, inflammation of the oral mucosa, purulent paronychia, dry skin, lack of appetite and itching.

InteractionsThis section has been translated automatically.

Afatinib is a substrate and inhibitor of P-glycoprotein. Corresponding drug interactions are possible with P-gp inhibitors and inducers.

S.a. Technical information

PreparationsThis section has been translated automatically.

Giotrif® (afatinib was approved in the USA and EU in 2013).

LiteratureThis section has been translated automatically.

  1. Chen X. et al (2013) Clinical perspective of afatinib in non-small cell lung cancer. Lung cancer 81: 155-61
  2. Giotrif 50mg Professional info (2020)
  3. Hirsh V. Afatinib (2011) Development in non-small-cell lung cancer. Future Oncol 7:817-825
  4. Nelson V et al (2013) Emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 6: 135-143
  5. Sequist E V et al (2013) Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology 31:3327-3334
  6. Yang J CH et al (2013): Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology 31:3342-3350

Authors

Last updated on: 27.02.2022